RECK

Across TCGA pan-cancer cohorts, RECK Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RECK data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RECK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RECK expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and LIHC are the cancer types where RECK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.168	0.690	<.001	32	view →
UCEC	DFS	Median	All	0.977	0.826	.009	16	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	12	view →
SARC	OS	Median	All	0.127	0.860	<.001	9	view →
READ	DFS	Median	II,III,IV	0.112	0.800	.002	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
COAD	OS	Median	All	0.289	0.685	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RECK–BLCA (OS)

Open the BLCA breakdown →